Risk factors for prolonged treatment of lymph node tuberculosis

Int J Tuberc Lung Dis. 2012;16(3):373-5. doi: 10.5588/ijtld.11.0470. Epub 2012 Jan 5.

Abstract

Lymph node tuberculosis (LNTB) is the most frequent form of extra-pulmonary tuberculosis (TB). Randomised, controlled trials have convincingly demonstrated that 6 months of chemotherapy is sufficient for most drug-susceptible LNTB. We performed a retrospective, multicentric study from 1997 to 2010 to describe factors associated with prolonged anti-tuberculosis treatment in patients with LNTB. Of 126 patients diagnosed with LNTB, 22 (17.5%) were human immunodeficiency virus (HIV) infected. The median treatment duration was 9 months (interquartile range, 6-12). Treatment was significantly longer in patients with HIV (P < 0.01), additional sites of TB (P < 0.01) or weight loss (P = 0.04). Factors independently associated with excessively lengthy treatment were HIV co-infection and the presence of other TB foci.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • HIV Infections / complications*
  • HIV Infections / epidemiology
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Tuberculosis / epidemiology
  • Tuberculosis / physiopathology
  • Tuberculosis, Lymph Node / drug therapy*
  • Weight Loss
  • Young Adult

Substances

  • Antitubercular Agents